Study of OCV-501 in Patients With Acute Myeloid Leukemia (AML) (Extension From Study 311-10-001)

• Status: Completed
• Trial end date: 2016-12-22
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess the safety of OCV-501 in patients with AML who completed the Study 311-10-001 and were judged that there was no relapse by any inspections in the end of the study.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Otsuka Pharmaceutical Co., Ltd.

Criteria

Inclusion Criteria:

• Patients who completed the Study 311-10-001 and were judged that there was no relapse by any inspections in the end of the study.

• Patients who are capable of giving informed consent

Exclusion Criteria:

• Patients failed to discontinue the Study 311-10-001 even though patients met the discontinuation criteria.

• Patients who have participated in any other clinical trials , excluding the Study 311-10-001).